August 19th 2023
According to Regeneron, the approval was based on data in the PULSAR and PHOTON trials, in which the drug demonstrated clinically equivalent vision gains to aflibercept Injection 2 mg that were maintained with fewer injections.
(COPE Credit) Community Practice Connections™: Comprehensive Key Advances in Biosimilars for Retinal Diseases – Reviewing the Evidence, Addressing Patient Perspectives, and Practice Utilization for the Retina Specialist
View More
(CME/CNE Credit) Community Practice Connections™: Comprehensive Key Advances in Biosimilars for Retinal Diseases – Reviewing the Evidence, Addressing Patient Perspectives, and Practice Utilization for the Retina Specialist
View More
Free COPE CE at AAOPT
Register Now!
Clinical Consultations: Individualizing Management of Uveitic Macular Edema - Clinical Updates in Treatment Options
View More
Enjoy these CME sessions at AAO 2023
Register Now!
C.R.U. Eye Symposium (Current, Relevant, Useful)
11/10/2023-11/12/2023
Register Now!
Community Practice Connections™: Ophthalmology and Oncology Perspectives on Integrating Novel Bispecific Antibodies Into the Uveal Melanoma Treatment Paradigm
View More
Medical Crossfire®: Ophthalmology and Oncology Perspectives on Integrating Novel Bispecific Antibodies Into the Uveal Melanoma Treatment Paradigm
View More
The Optometry Times EyeCon 2023
Register Now!
The Ophthalmology Times EyeCon 2023
Register Now!
(COPE Credit) Community Practice Connections™: Expert Approaches in Cataract Surgery – Managing Advances in Techniques and Technologies With an Updated Armamentarium
View More
(CME Credit) Community Practice Connections™: Expert Approaches in Cataract Surgery – Managing Advances in Techniques and Technologies With an Updated Armamentarium
View More
(CME/CNE Credit) MGD-Associated Dry Eye Disease – How Emerging Options May Shift the Treatment Paradigm
View More
(COPE Credit) MGD-Associated Dry Eye Disease – How Emerging Options May Shift the Treatment Paradigm
View More
(CME/CNE Credit) Expert Illustrations & Commentaries™: Envisioning New Therapies for Meibomian Gland Dysfunction-Associated DED
View More
(COPE Credit) Expert Illustrations & Commentaries™: Envisioning New Therapies for Meibomian Gland Dysfunction-Associated DED
View More
(COPE Credit) Patient, Provider, and Caregiver Connection™: Individualizing Care in Allergic Conjunctivitis – Understanding the Patient’s Perspective in Alleviating Disease Burden
View More
(CME Credit) Patient, Provider, and Caregiver Connection™: Individualizing Care in Allergic Conjunctivitis – Understanding the Patient’s Perspective in Alleviating Disease Burden
View More
Community Practice Connections™: 2nd Annual Optometry Times™ EyeCon
View More
Shared Perspectives in Managing Presbyopia – Understanding a New Paradigm for Optimizing Quality of Life
View More
Perfecting Co-Management of Glaucoma – Utilizing Development in the Spectrum of Treatment Options
View More
Community Practice Connections™: Ophthalmology Times® EyeCon 2022
View More
Expert Insights in Geographic Atrophy with Transformative Care on the Horizon – Understanding the Complement System as a Target for Treatment
View More
Medical Crossfire®: Expert Perspectives in Geographic Atrophy – How Can We Prepare for a New Era of Treatment?
View More
(COPE Credit) Addressing Healthcare Inequities Diabetic Retinal Vascular Disease: How Can We Address Ethnic Disparities within the Clinic?
View More
(CME Credit) Addressing Healthcare Inequities Diabetic Retinal Vascular Disease: How Can We Address Ethnic Disparities within the Clinic?
View More
(COPE Credit) Community Practice Connections™: Restoring the Surface – Impact of Preservatives and Novel Formulations in First Line Treatments for Dry Eye Disease
View More
(COPE Credit) Community Practice Connections™: Improving Management of MGD-Associated Dry Eye Disease—A Look to the Future of Treatment
View More
(CME/CNE Credit) Community Practice Connections™: Restoring the Surface Impact of Preservatives and Novel Formulations in First Line Treatments for Dry Eye Disease
View More
(CME/CNE Credit) Analyzing Novel Tear Stimulating Treatments for Special Populations in Dry Eye Disease
View More
Alimera nabs US commercial rights for Yutiq
May 18th 2023Today, Alimera Sciences announced that they have acquired the US commercial rights of Yutiq (fluocinolone acetonide intravitreal insert) 0.18mg for the treatment of chronic non-infectious uveitis. Yutiq now joins Iluvien (fluocinolone acetonide intravitreal insert) 0.19 mg for DME in Alimera’s retina portfolio.
Risk of VA loss link found between DME eyes initially treated and observed
April 25th 2022Investigators report a correlation between the risk of 5-letter visual acuity (VA) loss at 24 months for eyes with clinically significant diabetic macular edema (CSDME) and good VA initially treated and eyes that were initially observed in routine clinical practice.